-
1 month ago | 
ancavasculitisnews.com | Steve Bryson |Patricia Inacio |Andrea Lobo |Somi Igbene
Researchers have identified new contributors to the abnormal immune responses against the myeloperoxidase (MPO) enzyme that drive ANCA-associated vasculitis (AAV) in some patients. Specifically, these abnormal responses are marked by high numbers of memory B-cells that produce an antibody type called immunoglobulin M (IgM).
-
1 month ago | 
charcot-marie-toothnews.com | Young K Lee |Patricia Inacio |Andrea Lobo |Somi Igbene
Managers, directors, and administrators are always discussing methods of inspiring high engagement among workers. Studies suggest that highly engaged employees are good for a company’s culture. Such employees are invested in their company’s goals, demonstrate good productivity, and are just good for business. However, I often wonder if some of us are so focused on producing what others expect that we forget to consider what we ourselves want out of our lives.
-
Jan 13, 2025 | 
parkinsonsnewstoday.com | Mollie Lombardi |Marisa Wexler |Lindsey Shapiro |Somi Igbene
One of the many annoying, frustrating, and mysterious symptoms of Parkinson’s disease is micrographia. Micrographia is when your handwriting gets teeny-tiny and illegible over time. Like gait freezing, it’s one of those odd motor symptoms of Parkinson’s in which your mind knows what it wants to do, but the muscles in your body just can’t make it happen.
-
Nov 19, 2024 | 
charcot-marie-toothnews.com | Young K Lee |Somi Igbene
Those of us with Charcot-Marie-Tooth disease (CMT) know that it takes things from us in profound ways. For example, it chips away at our balance and leads to muscle atrophy. Because CMT symptoms often manifest in unpredictable ways, we can’t effectively plan for our future. As a result, many of us face a shorter health span than our able-bodied peers. This can lead to feelings of shame.
-
Nov 18, 2024 | 
sjogrenssyndromenews.com | Andrea Lobo |Somi Igbene |Margarida Maia |Steve Bryson
Johnson & Johnson’s antibody-based therapy candidate nipocalimab has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for treating adults with moderate to severe Sjögren’s disease. This status is meant to accelerate the development and regulatory review of investigational therapies intended to treat serious or life-threatening conditions — and is awarded based on preliminary evidence suggesting substantial improvement over available therapies.
-
Nov 5, 2024 | 
myelomaresearchnews.com | Steve Bryson |Lindsey Shapiro |Somi Igbene |Joana Carvalho
A standard autologous hematopoietic stem cell transplant (AHSCT) safely and effectively prolongs survival and delays cancer progression in adults with multiple myeloma, a large, real-world international study indicates. Disease relapse was reported in 15.7% in the first year after the transplant, and patients lived a median of 7.5 years and without signs of disease progression for a median of three years.
-
Oct 16, 2024 | 
ancavasculitisnews.com | Marisa Wexler |Somi Igbene |Steve Bryson |Andrea Lobo
ADX-097, an experimental tissue-targeted therapy that Q32 Bio is developing for ANCA-associated vasculitis (AAV) and other diseases marked by overactivity of the immune complement system, was well tolerated in a Phase 1 clinical trial involving healthy volunteers. The study’s data also indicated that ADX-097 showed a favorable pharmacological profile, according to the company, which will present full results from the trial in a poster at the American Society of Nephrology (ASN) Kidney Week 2024.
-
Oct 7, 2024 | 
sjogrenssyndromenews.com | Andrea Lobo |Somi Igbene |Marisa Wexler |Margarida Maia
An imaging test that measures damage to salivary glands may effectively be used, together with the presence of self-reactive antibodies, to diagnose Sjögren’s disease and determine disease staging. That’s according to a new study from China that investigated the use of the imaging test, called parotid sialography, alongside one for self-reactive antibodies, or autoantibodies, in achieving a correct diagnosis.
-
Sep 5, 2024 | 
charcot-marie-toothnews.com | Young K Lee |Margarida Maia |Somi Igbene
Like many, I’ve enjoyed watching incredible athletes showcase their abilities at this year’s Paris Olympics and Paralympics. The Olympic Games always remind me of all the forms athleticism can take. There are countless sports out there that are all recognized as valid and worthy endeavors on a global stage. Each event is a unique celebration of what the human body can achieve with talent and considerable hard work. It’s cliché, but I find it inspiring.
-
Aug 7, 2024 | 
charcot-marie-toothnews.com | Andrea Lobo |Margarida Maia |Patricia Inacio |Somi Igbene
Cochlear implants are a safe and reliable way to improve hearing, speech, and quality of life for people with Charcot-Marie-Tooth disease (CMT), according to a case series. This study provides “more evidence supporting the potential benefit of cochlear implantation among CMT patients,” researchers wrote.
